A Study of EP0031 in Patients With Advanced RET-altered Malignancies
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)
Inclusion Criteria
- Inclusion Criteria: Applicable to all patients: 1. Must be ≥18 years of age, with documented RET-altered cancers 2. Patients should be well informed and consented about alternative treatment options including approved RET-targeted therapies 3. ECOG performance status of 0 or 1 and life expectancy >3 months at screening 4. Ability to understand and provide written informed consent and able to participate in all required evaluations and procedures 5. Additional cohort specific criteria apply Exclusion Criteria: Patients with any of the following will not be included in the study: 1. Any known major driver gene alterations other than RET. 2. Spinal cord compression or brain metastases. Patients with stable brain metastases can be enrolled. 3. Active infection requiring systemic antibiotic, antifungal, or antiviral medication 4. Severe or uncontrolled medical condition or psychiatric condition 5. Chronic glomerulonephritis or renal transplant 6. Patients with active hepatitis B infection or active hepatitis C 7. Patients with active HIV infection. Patients living with HIV may be eligible if they have adequate CD4+ T-cell count and no history of AIDS-defining opportunistic infections in the past 12 months 8. Receipt of any strong inhibitor or inducer of CYP3A4 9. Impaired hepatic or renal function, inadequate bone marrow reserve or organ function 10. Any clinically important abnormalities in rhythm, conduction, or morphology on resting ECG or any factor that increases the risk of QTc prolongation or of arrhythmic events , or congestive heart failure Grade II-IV according to the New York Heart Association, myocardial infarction, or unstable angina within the previous 6 months 11. Uncontrolled hypertension 12. Corneal ulceration at screening
Additional locations may be listed on ClinicalTrials.gov for NCT05443126.
Locations matching your search criteria
United States
California
Palo Alto
District of Columbia
Washington
Illinois
Chicago
Kentucky
Lexington
Massachusetts
Boston
Missouri
Saint Louis
New York
New York
Pennsylvania
Philadelphia
Texas
Houston
Washington
Seattle
EP0031 is being investigated in this modular, interventional Phase I/II dose escalation
and dose expansion study to investigate the optimal dose in adult patients with advanced
RET-altered malignancies. Currently there are no approved RET-targeted treatments for
patients who progress on first-generation SRIs. However, it is proposed that EP0031 can
overcome resistance mechanisms to first generation SRIs, as EP0031 is a potent and
selective RET inhibitor with broad activity against common RET fusions and mutations.
Phase I (dose escalation and optimization) has completed and a RP2D has been selected for
Phase II.
Trial PhasePhase I/II
Trial Typetreatment
Lead OrganizationEllipses Pharma
- Primary IDEP0031-101
- Secondary IDsNCI-2022-10316
- ClinicalTrials.gov IDNCT05443126